Pfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −7.98%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
Follow PFE
Alert me
Pfizer Inc. (PFE) P/E ratio
As of 5 November 2026, Pfizer Inc. (PFE) trades at a P/E ratio of 42.2×. Over the past ten years it has ranged from 0.0× (September 2024) to 82.6× (January 2024); the current reading is higher than 98% of that period. That is above the Drug Manufacturers General industry median of 26.6× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 18.3× | (2.11%) |
| FY2024 | 18.7× | (77.35%) |
| FY2023 | 82.6× | 797.36% |
| FY2022 | 9.2× | (39.22%) |
| FY2021 | 15.1× | (29.25%) |
| FY2020 | 21.4× | 62.60% |
| FY2019 | 13.2× | (42.01%) |
| FY2018 | 22.7× | 127.48% |
| FY2017 | 10.0× | (63.81%) |
| FY2016 | 27.6× | 13.42% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 40.1× | 26.69% |
| Jun 2026 | 31.7× | 47.81% |
| Mar 2026 | 21.4× | 17.08% |
| Dec 2025 | 18.3× | 23.59% |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GILD Gilead Sciences, Inc. compare | n/m |
| NVO Novo Nordisk A/S compare | 9.9× |
| BMY Bristol Myers Squibb Company compare | 14.0× |
| GSK GSK PLC Sponsored ADR compare | 16.7× |
| SNY Sanofi compare | 23.2× |
| AZN AstraZeneca PLC compare | 26.3× |
| AMGN Amgen Inc. compare | 26.6× |
| NVS Novartis AG compare | 30.9× |
| PFE Pfizer Inc. | 42.2× |
| Drug Manufacturers General industry median | 26.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on PFE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement